Table 1.
Anthropometric, clinical and biochemical characteristics of the enrolled patients. *: All biochemical and DXA measurements were performed before the scheduled dose of denosumab (yrs, years; VF, vertebral fractures; NVF, non-vertebral fractures; NR, normal range; BMD, bone mineral density; LS, lumbar spine; LFN, left femoral veck; LTH, left total hip).
| Parameters | Values |
|---|---|
| Age (yrs) | 67.8 ± 9 |
| Age at menopause (yrs) | 46.28 ± 4.9 |
| Drug – naive patients (n,%) | 11, 36% |
| History of gastroesophageal reflux disease and/or peptic ulcer (n, %) | 9, 30% |
| Duration of previous treatment (yrs) | 5.1 ± 4 |
| Duration of treatment with denosumab | 3.1 ± 1.6 |
| Patients with a history of VF (n, %) | 6, 20% |
| Patients with a history of NVF (n, %) | 4, 13% |
| *Serum calcium (NR: 8.7-10.3 mg/dl) | 9.5 ± 0.5 |
| Serum phosphate (NR: 2.5-4.5 mg/dl) | 3.3 ± 0.7 |
| Serum creatinin (NR: 0.7-1.2 mg/dl) | 0.7 ± 0.14 |
| Serum PTH (NR: 11-54 pg/ml) | 47.4 ± 12.8 |
| Serum osteocalcin (NR: 9-42 ng/ml) | 10.6 ± 4.8 |
| BMD LS (gr/cm2) | 0.921 ± 0.12 |
| T-score LS | -2.03 ± 0.96 |
| BMD LFN (gr/cm2) | 0.743 ± 0.06 |
| T-score LFN | -2.02 ± 0.66 |
| BMD LTH (gr/cm2) | 0.808 ± 0.08 |
| T-score LTH | -1.54 ± 0.71 |